Experts discuss the disease burden and treatment landscape for age-related macular degeneration (AMD), and diabetic macular edema (DME).
EP. 4: Anti-VEGF and Gene Therapy Impacting Wet AMD and DME Treatment LandscapesFebruary 16th 2023
Dr Sheth discusses his insights on anti-VEGF therapy that he has noticed in the treatment of wet AMD over the last decade, and Caesar Luo, MD, FASRS, FACS shares his insight on new treatment options and their impact on patient access and cost considerations.
EP. 5: Variability of Frequency Dosing for Anti-VEGF Agents in the Treatment of Wet AMDFebruary 23rd 2023
Dr Coney discusses the variability of frequency dosing with anti-VEGF therapy in patients with wet AMD and DME, and Dr Sheth expands on Ang-2 and its contribution to the development of vascular instability in wet AMD.
EP. 6: Faricimab: Mechanism of Action, Payers’ Perspective, and Real-World ExperienceFebruary 23rd 2023
Key opinion leaders discuss faricimab, its impact on the treatment landscape for wet AMD/DME, and what payers should look for when considering formulary positioning or utilization-management strategies.